专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

151. 发明申请

WO2009011940A3 MICROCIN H47 PLASMID SELECTION SYSTEM 审中-公开
公开(公告)号：WO2009011940A3
公开(公告)日：2009-01-22
申请号：PCT/US2008/059214
申请日：2008-04-03
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , GALEN, James, E. , FANG, Chee-mun
发明人： GALEN, James, E. , FANG, Chee-mun
IPC分类号： C12N15/31 , C12N15/64 , C12N15/09
摘要： The present invention relates generally to stabilized expression plasmid systems. The stabilized expression plasmid systems comprise an expression vector that includes a plasmid maintenance system (PMS) and, optionally, one or both of a polynucleotide encoding a selected antigen under control of a promoter, and a polynucleotide encoding a selectable marker under control of a promoter. The use of the mchI protein as a selectable marker is found in preferred embodiments of the invention.

152. 发明申请

WO2008144485A2 INHIBITION OF PALMITOYL ACYL TRANSFERASE EXPRESSION AND/OR ACTIVITY FOR THE REGULATION OF ANTIPROLIFERATIVE FACTOR ACTIVITY 审中-公开
标题翻译：抑制丙氨酸转移酶表达和/或活性以调节抗增生因子活性
公开(公告)号：WO2008144485A2
公开(公告)日：2008-11-27
申请号：PCT/US2008/063860
申请日：2008-05-16
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. , KEAY, Susan, K. , ZACHARIAS, David , PLANEY, Sonia, L.
发明人： KEAY, Susan, K. , ZACHARIAS, David , PLANEY, Sonia, L.
IPC分类号： C07K1/00 , C12G1/00 , C12N15/12 , C12P21/00 , A61K39/39
CPC分类号： C07K14/71 , C12N9/1029 , C12N15/1137 , C12N2310/14
摘要： The invention generally concerns inhibition of a molecule that has a role in post- translational modification of a receptor for antiproliferative factor (APF) of bladder epithelial cells, thereby modulating the APF. In particular, inhibition of DHHC2 activity and/or ZDHHC2 expression results in modulation of APF receptor activity, and in specific aspects such modulation is therapeutic and/or preventative for a bladder condition, such as interstitial cystitis. In addition, inhibition of CKAP4 palmitoylation in certain cases also decreases its activity as a tPA receptor on smooth muscle cells or surfactant A on type II pneumocytes, and/or generally inhibits its function as a cell membrane receptor, cell chaperone molecule, and/or membrane trafficking agent.
摘要翻译：本发明通常涉及在膀胱上皮细胞的抗增殖因子（APF）受体的翻译后修饰中起作用的分子的抑制，从而调节APF。特别地，DHHC2活性和/或ZDHHC2表达的抑制导致APF受体活性的调节，并且在具体方面，这种调节是膀胱状况如间质性膀胱炎的治疗和/或预防性。另外，在某些情况下，CKAP4棕榈酰化的抑制也降低其作用于II型肺细胞上的平滑肌细胞或表面活性剂A上的tPA受体的活性，和/或通常抑制其作为细胞膜受体，细胞分子伴侣分子和/或膜转运剂。

153. 发明申请

WO2008076918A2 ANTI-CANCER AGENTS AND ANDROGEN INHIBITION ACTIVITY COMPOUND 审中-公开
标题翻译：抗癌药物和雄激素抑制活性化合物
公开(公告)号：WO2008076918A2
公开(公告)日：2008-06-26
申请号：PCT/US2007/087631
申请日：2007-12-14
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , NJAR, Vincent C., O. , PURUSHOTTAMACHAR, Puranik
发明人： NJAR, Vincent C., O. , PURUSHOTTAMACHAR, Puranik
IPC分类号： A61K31/18
CPC分类号： A61K31/18
摘要： A qualitative 3D pharmacophore model (a common feature based model or Catalyst HipHop algorithm) developed from well-known natural product androgen receptor down-regulating agents (ARDAs). The 3D pharmacophore model is used as a template in virtual screening compounds for new ARDAs. ARDA compounds and compounds that strongly inhibit the growth of human prostate LNCaP cells. The compounds may be used in compositions and methods of inhibiting cell proliferation of a cancer and methods of preventing or treating cancer, including prostate cancer.
摘要翻译：从众所周知的天然产物雄激素受体下调剂（ARDAs）开发的定性3D药效团模型（基于共同特征的模型或催化剂HipHop算法）。 3D药效团模型被用作新ARDAs的虚拟筛选化合物的模板。 ARDA化合物和强烈抑制人类前列腺LNCaP细胞生长的化合物。所述化合物可用于抑制癌症细胞增殖的组合物和方法以及预防或治疗癌症（包括前列腺癌）的方法。

154. 发明申请

WO2008067245A3 DETERMINING INSULIN PUMP RATE FOR TIGHT GLYCEMIC CONTROL 审中-公开
公开(公告)号：WO2008067245A3
公开(公告)日：2008-06-05
申请号：PCT/US2007/085518
申请日：2007-11-26
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , VAIDYA, Vinay , SHANHOLTZ, Carl Barton
发明人： VAIDYA, Vinay , SHANHOLTZ, Carl Barton
IPC分类号： A61M5/168
摘要： A method for controlling a patient's blood glucose includes receiving target selection data that indicates a particular target glucose level for a patient among multiple target glucose levels. Current glucose data and previous glucose data that indicate blood glucose levels for a particular patient are also received. Current insulin data that indicates a rate at which insulin is currently being administered intravenously to the particular patient is also received. Based on the target selection data, the current glucose data and the previous glucose data, recommended insulin data is determined. The recommended insulin data indicates a rate at which insulin should be administered to the particular patient to achieve the particular target glucose level. In some embodiments, recommended measurement data that indicates a time at which to make a next measurement of blood glucose level for the particular patient is also determined.

155. 发明申请

WO2008066887A2 SMALL MOLECULE INHIBITORS OF BCL6 审中-公开
标题翻译： BCL6的小分子抑制剂
公开(公告)号：WO2008066887A2
公开(公告)日：2008-06-05
申请号：PCT/US2007/024571
申请日：2007-11-29
申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY , UNIVERSITY OF MARYLAND, BALTIMORE , UNIVERSITY HEALTH NETWORK , MELNICK, Ari, Matthew , MACKERELL, Alexander, D., Jr. , PRIVE, Gilbert, Gerard
发明人： MELNICK, Ari, Matthew , MACKERELL, Alexander, D., Jr. , PRIVE, Gilbert, Gerard
IPC分类号： A61K31/415
CPC分类号： A61K31/415 , C07D417/04
摘要： Provided are methods of inhibiting BCL6 repression in a mammalian cell. Also provided are methods of treating cancer in a mammal.
摘要翻译：提供了抑制哺乳动物细胞中BCL6阻遏的方法。还提供了治疗哺乳动物癌症的方法。

156. 发明申请

WO2007146802A3 SYSTEM AND COMPOSITIONS FOR ISOLATING SUPPRESSORS OF HIV-1 PROTEASE 审中-公开
公开(公告)号：WO2007146802A3
公开(公告)日：2007-12-21
申请号：PCT/US2007/070757
申请日：2007-06-08
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , ZHAO, Richard, Y. , ELDER, Robert, T.
发明人： ZHAO, Richard, Y. , ELDER, Robert, T.
IPC分类号： C12Q1/37 , C12Q1/02
摘要： The present invention relates to a yeast screening assay for the identification of suppressors of a protease, such as the HIV-I protease and/or HIV-2 protease, for example. Upon overexpression of HIV-I protease in Schizosaccharomyces pombe, for example, the cell dies, but in the presence of a candidate inhibitor with protease suppressor activity, the cell lives, thereby providing an assay for the identification of one or more suppressors. In additional aspects, there is an in vivo protease activity screen, used alternatively or additionally to a viability screen, such as for cleavage of a HIV-I protease-specific site. In further aspects, the suppressor is employed for the treatment of an individual infected with HIV virus or with AIDS.

157. 发明申请

WO2007134241A2 NASAL DELIVERY OF THERAPEUTIC AGENTS USING TIGHT JUNCTION AGONISTS 审中-公开
标题翻译：使用轻微结肠激素治疗药物的NASAL递送
公开(公告)号：WO2007134241A2
公开(公告)日：2007-11-22
申请号：PCT/US2007/068792
申请日：2007-05-11
申请人： UNIVERSITY OF MARYLAND BALTIMORE , EDDINGTON, Natalie, D. , SONG, Keon-Hyoung , TEKSIN, Zeynep , CROSS, Alan, A.
发明人： EDDINGTON, Natalie, D. , SONG, Keon-Hyoung , TEKSIN, Zeynep , CROSS, Alan, A.
IPC分类号： G06F21/22
CPC分类号： A61K45/06 , A61K31/4725 , A61K31/7072 , A61K31/733 , A61K38/04 , A61K38/13 , A61K2300/00
摘要： The invention relates to a therapeutic composition comprising a therapeutically effective amount of one or more therapeutic agents and a nasal mucosa absorption-enhancing amount of one or more tight junction agonists. The invention further relates to a method of treating a subject comprising intranasally administering the composition of the invention to the subject.
摘要翻译：本发明涉及包含治疗有效量的一种或多种治疗剂和鼻粘膜吸收增强量的一种或多种紧密结合激动剂的治疗组合物。本发明还涉及一种治疗受试者的方法，所述方法包括向受试者鼻内施用本发明的组合物。

158. 发明申请

WO2007070888A1 METHYLATION OF GENE PROMOTERS AS A PREDICTOR OF EFFECTIVENESS OF THERAPY 审中-公开
标题翻译：作为治疗效果预测因子的基因启动子的甲基化
公开(公告)号：WO2007070888A1
公开(公告)日：2007-06-21
申请号：PCT/US2006/062242
申请日：2006-12-18
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , MELTZER, Stephen, J. , HAMILTON, James, P. , SATO, Fumiaki
发明人： MELTZER, Stephen, J. , HAMILTON, James, P. , SATO, Fumiaki
IPC分类号： G01N33/574
CPC分类号： C12Q1/6886 , C12Q2523/125 , C12Q2600/106 , C12Q2600/154 , C12Q2600/156
摘要： The present invention provides methods for identifying, diagnosing, evaluating or monitoring a disease state in a subject comprising identifying the methylation status of a panel of genes in the subject. The present invention also relates to identifying, diagnosing, evaluating or monitoring the responsiveness of a subject to a therapeutic regimen, with the methods comprising determining the methylation status of a panel of genes in the subject.
摘要翻译：本发明提供用于鉴定，诊断，评估或监测受试者中疾病状态的方法，包括鉴定受试者中一组基因的甲基化状态。本发明还涉及鉴定，诊断，评估或监测受试者对治疗方案的反应性，其方法包括测定受试者中一组基因的甲基化状态。

159. 发明申请

WO2007050606A2 DETOXIFIED ENDOTOXIN VACCINE AND ADJUVANT AND USES THEREOF 审中-公开
标题翻译：脱毒的内毒素疫苗和佐剂及其用途
公开(公告)号：WO2007050606A2
公开(公告)日：2007-05-03
申请号：PCT/US2006/041477
申请日：2006-10-24
申请人： THE UNIVERSITY OF MARYLAND, BALTIMORE , CROSS, Alan , BHATTACHARJEE, Apurba, K. , ZOLLINGER, Wendell , OPAL, Steven
发明人： CROSS, Alan , BHATTACHARJEE, Apurba, K. , ZOLLINGER, Wendell , OPAL, Steven
IPC分类号： A61K39/108
CPC分类号： A61K39/025 , A61K39/0258 , A61K39/095 , A61K2039/55561 , Y02A50/474
摘要： The present invention describes a detoxified Gram negative J5 core lipopolysaccharide/grop B meningococcal outer membrane protein complex vaccine given in conjunction with CpG 7909 adjuvant. This vaccine composition can be used for either active or passive immunization of mammals for the prevention or treatment of sepsis and infection with Gram negative bacteria. The addition of CpG to the vaccine was shown to markedly increase the antibody response in mice. Furthermore, the ability of the endotoxin vaccine in protecting against Gram-negative bacteria such as Francisella tularensis in vivo is also demonstrated herein.
摘要翻译：本发明描述了与CpG 7909佐剂联合给予的解毒的革兰氏阴性J5核心脂多糖/ grop B脑膜炎球菌外膜蛋白复合物疫苗。该疫苗组合物可以用于哺乳动物的主动或被动免疫，用于预防或治疗败血症和革兰氏阴性菌感染。显示向疫苗中添加CpG显着增加小鼠中的抗体应答。此外，本文还证明了内毒素疫苗在体内保护免受革兰氏阴性细菌如土拉弗朗西斯菌的能力。

160. 发明申请

WO2007046962A2 CELL LINES HARBORING HEPATITIS VIRUS AND METHODS FOR USING THEREOF 审中-公开
标题翻译：细胞系吸入性肝炎病毒及其使用方法
公开(公告)号：WO2007046962A2
公开(公告)日：2007-04-26
申请号：PCT/US2006/034442
申请日：2006-09-05
申请人： THE UNIVERSITY OF MARYLAND, BALTIMORE , OLDACH, David , HEYWARD, Scott , SILBER, Paul
发明人： OLDACH, David , HEYWARD, Scott , SILBER, Paul
IPC分类号： C12N7/00
CPC分类号： C12N7/00 , C12N2770/24251 , G01N33/5767
摘要： The present invention relates to cryopreserved primary hepatocytes infected with hepatitis C virus (HCV), which, when thawed and cultured, are capable of being infected with and releasing infectious HCV. The present invention also relates to methods of producing primary cryopreserved hepatocytes infected with hepatitis C virus (HCV), wherein the HCV-infected primary hepatocytes are capable of releasing new infectious HCV. The present invention also relates to methods of using HCV-infected primary hepatocytes to screen drug candidates for their ability to affect HCV infection and/or replication. The invention also relates to methods of producing infectious HCV in vitro and methods of using this infectious HCV such as, but not limited to, preparing vaccines directed towards HCV, its receptor or virus-receptor intermediate states.
摘要翻译：本发明涉及感染丙型肝炎病毒（HCV）的冷冻保存的原代肝细胞，其在解冻和培养时能够感染和释放感染性HCV。本发明还涉及感染丙型肝炎病毒（HCV）的初级冷冻保存肝细胞的方法，其中HCV感染的原代肝细胞能够释放新的感染性HCV。本发明还涉及使用HCV感染的原代肝细胞筛选候选药物以影响HCV感染和/或复制的能力的方法。本发明还涉及在体外产生感染性HCV的方法和使用这种感染性HCV的方法，例如但不限于制备针对HCV，其受体或病毒 - 受体中间状态的疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式